<DOC>
	<DOCNO>NCT02824718</DOCNO>
	<brief_summary>Hypoparathyroidism rare condition parathyroid gland fail produce sufficient amount parathyroid hormone parathyroid hormone produce lack biologic activity . The common cause hypoparathyroidism damage removal parathyroid gland due neck surgery another condition . Hypoparathyroidism also cause autoimmune process . In rare case , hypoparathyroidism may occur genetic disorder inherit autosomal recessive , autosomal dominant X-linked recessive trait . The autosomal dominant hypocalcemia ( ADH ) mainly cause heterozygous activate mutation CASR gene encode CaSR ) . ADH differs cause hypoparathyroidism increase risk develop hypercalciuria nephrolithiasis . The purpose study compare two therapeutic approach ADH order limit risk nephrocalcinosis renal failure attempt correct hypocalcemia : rhPTH ( 1-34 ) v association active vitamin D hydrochlorothiazide .</brief_summary>
	<brief_title>Recombinant Human rhPTH ( 1-34 ) VS Association Alfacalcidol/Hydrochlorothiazide Autosomal Dominant Hypocalcemia</brief_title>
	<detailed_description>The design consist five-periods , two-treatments , open-label , randomize , crossover study blind end-point evaluation . Patients come inclusion visit receive treatment 0.5 µg/day alfacalcidol 4 week ( 28±3 day , run-in ) . They instruct maintain dietary calcium intake ( 1 g/day ) duration study supplement throughout study native vitamin D order maintain concentration 25OH vitamin D ≥ 40 ng/L . Magnesium supplementation ( 100 mg/day ) maintain throughout study . At inclusion , patient randomly assign receive end run-in period , cross-over either association hydrochlorothiazide 25 mg/day ( ESIDREX® ) + amiloride 5 mg/day ( MODAMIDE® ) + 0.5 µg/day alfacalcidol ( ALFACALCIDOL® ) 40 µg/day rhPTH ( 1-34 ) ( teriparatide FORSTEO® 20 µg twice daily ) 7 8 week ( 52±3 day ) . After washout period 28±3 day 0.5 µg alfacalcidol /day , patient follow second period treatment . The study end final period 28±3 day 0.5 µg alfacalcidol /day . Patients ambulatory monitor serum calcium , sodium , potassium , creatinine level day 15 run run period day 7 day 28 treatment period .</detailed_description>
	<mesh_term>Hypocalcemia</mesh_term>
	<mesh_term>Alfacalcidol</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<mesh_term>Hydroxycholecalciferols</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Diuretics , Potassium Sparing</mesh_term>
	<mesh_term>Sodium Channel Blockers</mesh_term>
	<criteria>Inclusion criterion : Patients age 18 80 year , sex With genetically prove ADH type 1 ( CASR activate mutation ) Affiliated French health insurance system , consent study . Exclusion criterion : Pregnant breastfeed woman ; Women childbearing age without contraception ; For men age 18 20 year , presence cartilage growth Xray leave knee ; Anuria ; Kidney failure plasmatic creatinine &gt; 125 mmol/l urea &gt; 10 mmol/l ; Long QT interval : QTc &gt; 450 m ( men ) 470 m ( woman ) ; Hepatic failure ; Metabolic bone disease ( Paget 's disease bone ) primary osteoporosis glucocorticoidinduced osteoporosis ; Association potassium spar diuretic ; Hypokalemia ( &lt; 3.5 mmol/l ) without diuretic therapy ; Hyperkalemia ( &gt; 5.5 mmol/l ) ; Hyponatremia ( &lt; 135 mmol/l ) without diuretic therapy ; Hypercalcemia ( &gt; 2.6 mmol/l ) ; Severe hypomagnesemia ( ≤ 0.5 mmol/l ) ; Vitamin D deficiency ( 25OH vit D &lt; 20 ng/mL ) ; Unexplained increase alkaline phosphatase ( &gt; 2N ) ; Intolerance sulfamide ; Intolerance amiloride component drug ; Hypersensitivity active substance excipient one experimental drug ; Gluten intolerance ; Bone break history within three previous month ; History radiotherapy skeleton ; History bone cancer metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hypoparathyroidism</keyword>
	<keyword>PTH ( 1-34 )</keyword>
	<keyword>Thiazides</keyword>
	<keyword>Hypercalciuria</keyword>
	<keyword>Calcium sense receptor</keyword>
</DOC>